MFS Charter Income Trust is a diversified closed-end management investment company. The company has market cap of $462.64 million. The Fund’s investment objective is to seek high current income, but may also consider capital appreciation. It currently has negative earnings. The Fund normally invests in debt instruments.
The stock of Neurotrope Inc (NASDAQ:NTRP) is a huge mover today! About 122,230 shares traded or 61.19% up from the average. Neurotrope Inc (NASDAQ:NTRP) has risen 6.00% since March 11, 2017 and is uptrending. It has underperformed by 2.51% the S&P500.The move comes after 8 months positive chart setup for the $161.49 million company. It was reported on Apr, 10 by Barchart.com. We have $22.35 PT which if reached, will make NASDAQ:NTRP worth $12.92 million more.
Saba Capital Management L.P. holds 1.23% of its portfolio in MFS Charter Income Trust for 1.42 million shares. 1607 Capital Partners Llc owns 1.32 million shares or 0.76% of their US portfolio. Moreover, Rivernorth Capital Management Llc has 0.57% invested in the company for 1.02 million shares. The Minnesota-based Sit Investment Associates Inc has invested 0.41% in the stock. Benchmark Capital Advisors, a New York-based fund reported 53,650 shares.
About 127,641 shares traded. MFS Charter Income Trust (NYSE:MCR) has declined 0.92% since September 1, 2016 and is downtrending. It has underperformed by 9.42% the S&P500.
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical firm with its product candidates in pre-clinical and clinical development. The company has market cap of $161.49 million. The Firm is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease , which is in the clinical testing stage. It currently has negative earnings. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing.
